Gemini Therapeutics (GMTX)
NASDAQ:GMTX
US Market
Holding GMTX?
Track your performance easily

Gemini Therapeutics (GMTX) Income Statement

116 Followers

Gemini Therapeutics Income Statement

Last quarter (Q3 2022), Gemini Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, Gemini Therapeutics's net income was $-3.28M. See Gemini Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 21Dec 20
Total Revenue
-$ 0.00$ 0.00
Cost of Revenue
---
Gross Profit
---
Operating Expense
$ 43.89M$ 69.00M$ 34.04M
Operating Income
$ -43.89M$ -69.00M$ -34.04M
Net Non Operating Interest Income Expense
$ 421.00K$ -2.14M$ -6.79M
Other Income Expense
$ 48.00K$ -724.00K$ -8.00K
Pretax Income
$ -43.42M$ -71.87M$ -40.84M
Tax Provision
--$ 0.00
Earnings From Equity Interest Net Of Tax
---
Net Income Common Stockholders
$ -43.42M$ -71.87M$ -40.84M
Basic EPS
$ -1.00$ -1.78$ -2.70
Diluted EPS
$ -1.00$ -1.78$ -2.70
Basic Average Shares
$ 172.87M$ 40.36M$ 15.12M
Diluted Average Shares
$ 172.87M$ 40.36M$ 15.12M
Dividend Per Share
---
Total Operating Income As Reported
---
Reported Normalized Basic E P S
---
Reported Normalized Diluted E P S
---
Rent Expense Supplemental
---
Total Expenses
$ 43.89M$ 69.00M$ 34.04M
Net Income From Continuing And Discontinued Operation
$ -43.42M$ -71.87M$ -40.84M
Normalized Income
$ -43.42M$ -71.87M$ -40.83M
Interest Expense
$ 240.00K$ 2.16M$ 6.83M
EBIT
$ -43.18M$ -69.71M$ -34.01M
EBITDA
$ -43.13M$ -69.48M$ -33.69M
Currency in USD

Gemini Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis